Literature DB >> 16441078

Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.

Wayne W Harding1, Matthew Schmidt, Kevin Tidgewell, Pavitra Kannan, Kenneth G Holden, Brian Gilmour, Hernan Navarro, Richard B Rothman, Thomas E Prisinzano.   

Abstract

Salvinorin A (1) is a hallucinogenic neoclerodane diterpene isolated from the widely available psychoactive plant Salvia divinorum and is the first example of a non-nitrogenous opioid receptor ligand. At present, there is little information available as to why this compound is selective for kappa opioid receptors. One approach to better understanding the mode of binding of 1 at kappa receptors is to systematically alter the structure of 1 and examine the effects on opioid receptor affinity and activity. Currently, there is a paucity of methods described for the preparation of analogues derived from 1. Here, we report the investigation of several chemical transformations of 1 isolated from S. divinorum. In particular, this work provides a semisynthesis of salvinicins A (2) and B (3) and has identified 10a as the first neoclerodane diterpene with delta opioid antagonist activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441078      PMCID: PMC2544632          DOI: 10.1021/np050398i

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  17 in total

Review 1.  Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

Authors:  Douglas J Sheffler; Bryan L Roth
Journal:  Trends Pharmacol Sci       Date:  2003-03       Impact factor: 14.819

2.  Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.

Authors:  David Y W Lee; Vishnu V R Karnati; Minsheng He; Lee-Yuan Liu-Chen; Leelakrishna Kondaveti; Zhongze Ma; Yulin Wang; Yong Chen; Cecile Beguin; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem Lett       Date:  2005-08-15       Impact factor: 2.823

3.  New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.

Authors:  David Y W Lee; Zhongze Ma; Lee-Yuan Liu-Chen; Yulin Wang; Yong Chen; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem       Date:  2005-10-01       Impact factor: 3.641

4.  A one-step synthesis of a deuterated paclitaxel analogue: 10-deacetoxy-(10alpha-2H)paclitaxel.

Authors:  D Dutta; H Hadd; D G Vander Velde; G I Georg
Journal:  Bioorg Med Chem Lett       Date:  1999-12-06       Impact factor: 2.823

5.  Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist.

Authors:  Thomas A Munro; Mark A Rizzacasa; Bryan L Roth; Beth A Toth; Feng Yan
Journal:  J Med Chem       Date:  2005-01-27       Impact factor: 7.446

6.  Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.

Authors:  David Y W Lee; Minsheng He; Leelakrishna Kondaveti; Lee-Yuan Liu-Chen; Zhongze Ma; Yulin Wang; Yong Chen; Jian-Guo Li; Cecile Beguin; William A Carlezon; Bruce Cohen
Journal:  Bioorg Med Chem Lett       Date:  2005-10-01       Impact factor: 2.823

7.  Salvinicins A and B, new neoclerodane diterpenes from Salvia divinorum.

Authors:  Wayne W Harding; Kevin Tidgewell; Matthew Schmidt; Kushal Shah; Christina M Dersch; John Snyder; Damon Parrish; Jeffrey R Deschamps; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Lett       Date:  2005-07-07       Impact factor: 6.005

8.  Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.

Authors:  Wayne W Harding; Kevin Tidgewell; Nathan Byrd; Howard Cobb; Christina M Dersch; Eduardo R Butelman; Richard B Rothman; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

9.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

10.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

Authors:  Bryan L Roth; Karen Baner; Richard Westkaemper; Daniel Siebert; Kenner C Rice; SeAnna Steinberg; Paul Ernsberger; Richard B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

View more
  22 in total

1.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

Review 2.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

3.  Potential Drug Abuse Therapeutics Derived from the Hallucinogenic Natural Product Salvinorin A.

Authors:  Katherine M Prevatt-Smith; Kimberly M Lovell; Denise S Simpson; Victor W Day; Justin T Douglas; Peter Bosch; Christina M Dersch; Richard B Rothman; Bronwyn Kivell; Thomas E Prisinzano
Journal:  Medchemcomm       Date:  2011-12       Impact factor: 3.597

Review 4.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 5.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

6.  Semisynthetic neoclerodanes as kappa opioid receptor probes.

Authors:  Kimberly M Lovell; Tamara Vasiljevik; Juan J Araya; Anthony Lozama; Katherine M Prevatt-Smith; Victor W Day; Christina M Dersch; Richard B Rothman; Eduardo R Butelman; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Bioorg Med Chem       Date:  2012-03-01       Impact factor: 3.641

7.  Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.

Authors:  Cécile Béguin; Katharine K Duncan; Thomas A Munro; Douglas M Ho; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen
Journal:  Bioorg Med Chem       Date:  2008-12-14       Impact factor: 3.641

8.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

9.  Unusual hemiacetal structure derived from Salvinorin A.

Authors:  Paulo Carvalho; Ruslan Bikbulatov; Jordan K Zjawiony; Mitchell A Avery
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-06-28

Review 10.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.